1,2,2,6,6-Pentamethylpiperidin-tartrat | 546-48-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1,2,2,6,6-Pentamethylpiperidin-tartrat
• 英文别名: pempidine hydrogen tartrate；Pharmakon1600-01503383；2,3-dihydroxybutanedioic acid;1,2,2,6,6-pentamethylpiperidine
• CAS: 546-48-5
• 化学式: C₄H₆O₆*C₁₀H₂₁N
• 分子量: 305.371
• InChiKey: AAFNEINEQRQMTF-UHFFFAOYSA-N

物化性质

• 熔点：
  150-151 °C(lit.)
• 沸点：
  178°C
• 密度：
  0.947

计算性质

• 辛醇/水分配系数(LogP)：
  0.54
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  118
• 氢给体数：
  4
• 氢受体数：
  7

安全信息

• 危险等级：
  3.2
• 危险品标志：
  Xn
• 危险类别码：
  R22
• 危险品运输编号：
  UN 2811 6.1/PG 3
• 海关编码：
  2915390090
• 包装等级：
  III
• 危险类别：
  3.2

制备方法与用途

用途是直接替代乙二醇乙醚醋酸酯最理想的溶剂，对极性和非极性物质均有很强的溶解能力。它适用于高档涂料、油墨及各种聚合物的溶剂，包括氨基甲基酸酯、乙烯基、聚酯、纤维素醋酸酯、醇酸树脂、丙烯酸树脂、环氧树脂以及硝化纤维素等。其中，丙二醇甲醚丙酸酯是一种新一代性能优良的绿色环保护溶剂。

文献信息

• Systems and methods for cardiac plexus neuromodulation
  申请人：Tulavi Therapeutics, Inc.

  公开号：US11446359B2

  公开（公告）日：2022-09-20

  Methods, devices and systems are described for decreasing the activity of the sympathetic nervous innervation to and from the lungs and the vessels supplying the lungs to treat pulmonary medical conditions such as asthma. In one embodiment, the method may involve advancing an intravascular instrument to a target location in a blood vessel within the intercostal vasculature to ablate either or both the sympathetic afferent and efferent nerves lying within the paravertebral gutter including the visceral fibers that travel to the cardiothoracic cavity and abdominopelvic viscera and the T1 to T4/5 sympathetic chain. In another embodiment, an intravascular instrument may be advanced to the bronchial vessels to ablate either or both the sympathetic afferent and efferent nerves in and around the posterior pulmonary plexus. In one embodiment the ablative agent is a neurolytic agent delivered in a gel. This approach may be utilized to treat other cardiac and pulmonary diseases.

  所述方法、装置和系统用于降低进出肺部和供应肺部的血管的交感神经神经支配的活性，以治疗哮喘等肺部疾病。在一个实施方案中，该方法可能涉及将血管内仪器推进到肋间血管内的目标位置，以消融位于椎旁沟内的交感神经传入和传出神经，包括通向心胸腔和腹盆腔内脏的内脏纤维以及 T1 至 T4/5 交感神经链。在另一个实施方案中，可将血管内器械推进到支气管，以消融后肺丛及其周围的交感传入和传出神经中的一条或两条。在一个实施方案中，消融剂是以凝胶形式递送的神经溶解剂。这种方法可用于治疗其他心脏和肺部疾病。
• SYSTEMS AND MEHTODS FOR SYMPATHETIC CARDIOPULMONARY NEUROMODULATION
  申请人：Reflex Medical Inc.

  公开号：EP3288626A1

  公开（公告）日：2018-03-07
• SYSTEMS AND METHODS FOR GEL-BASED NEUROMODULATION
  申请人：Tulavi Therapeutics, Inc.

  公开号：EP3764990A1

  公开（公告）日：2021-01-20
• SYSTEMS AND METHODS FOR SYMPATHETIC CARDIOPULMONARY NEUROMODULATION
  申请人：Reflex Medical, Inc.

  公开号：US20160317621A1

  公开（公告）日：2016-11-03

  Methods, devices and systems are described for decreasing the activity of the sympathetic nervous innervation to and from the lungs and the vessels supplying the lungs to treat pulmonary medical conditions such as asthma. In one embodiment, the method may involve advancing an intravascular instrument to a target location in a blood vessel within the intercostal vasculature to ablate either or both the sympathetic afferent and efferent nerves lying within the paravertebral gutter including the visceral fibers that travel to the cardiothoracic cavity and abdominopelvic viscera and the T1 to T4/5 sympathetic chain. In another embodiment, an intravascular instrument may be advanced to the bronchial vessels to ablate either or both the sympathetic afferent and efferent nerves in and around the posterior pulmonary plexus. In one embodiment the ablative agent is a neurolytic agent delivered in a gel. This approach may be utilized to treat other cardiac and pulmonary diseases.
• SYSTEMS AND METHODS FOR CARDIAC PLEXUS NEUROMODULATION
  申请人：Tulavi Therapeutics, Inc.

  公开号：US20190216899A1

  公开（公告）日：2019-07-18

  Methods, devices and systems are described for decreasing the activity of the sympathetic nervous innervation to and from the lungs and the vessels supplying the lungs to treat pulmonary medical conditions such as asthma. In one embodiment, the method may involve advancing an intravascular instrument to a target location in a blood vessel within the intercostal vasculature to ablate either or both the sympathetic afferent and efferent nerves lying within the paravertebral gutter including the visceral fibers that travel to the cardiothoracic cavity and abdominopelvic viscera and the T1 to T4/5 sympathetic chain. In another embodiment, an intravascular instrument may be advanced to the bronchial vessels to ablate either or both the sympathetic afferent and efferent nerves in and around the posterior pulmonary plexus. In one embodiment the ablative agent is a neurolytic agent delivered in a gel. This approach may be utilized to treat other cardiac and pulmonary diseases.